Targeting type 1FN in immune-mediated inflammatory disease
1200-1300 Online Speakers: Dr Hussein Al-Mossawi (Global Clinical Head for Anifrolumab, Late Respiratory and Immunology) Company: AstraZeneca Building on decades of research, AstraZeneca is starting to unravel complex inflammatory cell signalling pathways and uncover key drivers that cause an imbalance in immune-mediated diseases. This seminar is part of the University of Oxford Medical Sciences Division’s, […]